The science and practice of bone health in oncology

Managing bone loss and metastasis in patients with solid tumors

Allan Lipton, Robert Uzzo, Robert J. Amato, Georgiana K. Ellis, Behrooz Hakimian, G. David Roodman, Matthew R. Smith

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Cancer and its treatment can compromise bone health, leading to fracture, pain, loss of mobility, and hypercalcemia of malignancy. Bone metastasis occurs frequently in advanced prostate and breast cancers, and bony manifestations are commonplace in multiple myeloma. Osteoporosis and osteopenia may be consequences of androgen-deprivation therapy for prostate cancer, aromatase inhibition for breast cancer, or chemotherapy-induced ovarian failure. Osteoporotic bone loss and bone metastasis ultimately share a pathophysiologic pathway that stimulates bone resorption by increasing the formation and activity of osteoclasts. Important mediators of pathologic bone metabolism include substances produced by osteoblasts, such as RANKL, the receptor activator of nuclear factor kappa B ligand, which spurs osteoclast differentiation from myeloid cells. Available therapies are targeted to various steps in cascade of bone metastasis.

Original languageEnglish
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume7
Issue numberSUPPL. 7
StatePublished - 2009
Externally publishedYes

Fingerprint

Neoplasm Metastasis
Bone and Bones
Health
Osteoclasts
Neoplasms
Prostatic Neoplasms
Breast Neoplasms
RANK Ligand
Aromatase
Metabolic Bone Diseases
Hypercalcemia
Myeloid Cells
Bone Resorption
Osteoblasts
Multiple Myeloma
Androgens
Osteoporosis
Therapeutics
Drug Therapy
Pain

Keywords

  • Biochemical markers
  • Bisphosphonates
  • Bone health
  • Bone metabolism
  • Bone metastasis
  • Bone pain
  • Breast cancer
  • Chemotherapy-induced bone loss
  • Denosumab
  • Metastatic cancer
  • Multiple myeloma
  • Osteoporosis
  • Prostate cancer
  • RANKL

ASJC Scopus subject areas

  • Oncology

Cite this

The science and practice of bone health in oncology : Managing bone loss and metastasis in patients with solid tumors. / Lipton, Allan; Uzzo, Robert; Amato, Robert J.; Ellis, Georgiana K.; Hakimian, Behrooz; Roodman, G. David; Smith, Matthew R.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 7, No. SUPPL. 7, 2009.

Research output: Contribution to journalArticle

Lipton, Allan ; Uzzo, Robert ; Amato, Robert J. ; Ellis, Georgiana K. ; Hakimian, Behrooz ; Roodman, G. David ; Smith, Matthew R. / The science and practice of bone health in oncology : Managing bone loss and metastasis in patients with solid tumors. In: JNCCN Journal of the National Comprehensive Cancer Network. 2009 ; Vol. 7, No. SUPPL. 7.
@article{0fce55a7221642b59d7758e0a3bfff18,
title = "The science and practice of bone health in oncology: Managing bone loss and metastasis in patients with solid tumors",
abstract = "Cancer and its treatment can compromise bone health, leading to fracture, pain, loss of mobility, and hypercalcemia of malignancy. Bone metastasis occurs frequently in advanced prostate and breast cancers, and bony manifestations are commonplace in multiple myeloma. Osteoporosis and osteopenia may be consequences of androgen-deprivation therapy for prostate cancer, aromatase inhibition for breast cancer, or chemotherapy-induced ovarian failure. Osteoporotic bone loss and bone metastasis ultimately share a pathophysiologic pathway that stimulates bone resorption by increasing the formation and activity of osteoclasts. Important mediators of pathologic bone metabolism include substances produced by osteoblasts, such as RANKL, the receptor activator of nuclear factor kappa B ligand, which spurs osteoclast differentiation from myeloid cells. Available therapies are targeted to various steps in cascade of bone metastasis.",
keywords = "Biochemical markers, Bisphosphonates, Bone health, Bone metabolism, Bone metastasis, Bone pain, Breast cancer, Chemotherapy-induced bone loss, Denosumab, Metastatic cancer, Multiple myeloma, Osteoporosis, Prostate cancer, RANKL",
author = "Allan Lipton and Robert Uzzo and Amato, {Robert J.} and Ellis, {Georgiana K.} and Behrooz Hakimian and Roodman, {G. David} and Smith, {Matthew R.}",
year = "2009",
language = "English",
volume = "7",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "SUPPL. 7",

}

TY - JOUR

T1 - The science and practice of bone health in oncology

T2 - Managing bone loss and metastasis in patients with solid tumors

AU - Lipton, Allan

AU - Uzzo, Robert

AU - Amato, Robert J.

AU - Ellis, Georgiana K.

AU - Hakimian, Behrooz

AU - Roodman, G. David

AU - Smith, Matthew R.

PY - 2009

Y1 - 2009

N2 - Cancer and its treatment can compromise bone health, leading to fracture, pain, loss of mobility, and hypercalcemia of malignancy. Bone metastasis occurs frequently in advanced prostate and breast cancers, and bony manifestations are commonplace in multiple myeloma. Osteoporosis and osteopenia may be consequences of androgen-deprivation therapy for prostate cancer, aromatase inhibition for breast cancer, or chemotherapy-induced ovarian failure. Osteoporotic bone loss and bone metastasis ultimately share a pathophysiologic pathway that stimulates bone resorption by increasing the formation and activity of osteoclasts. Important mediators of pathologic bone metabolism include substances produced by osteoblasts, such as RANKL, the receptor activator of nuclear factor kappa B ligand, which spurs osteoclast differentiation from myeloid cells. Available therapies are targeted to various steps in cascade of bone metastasis.

AB - Cancer and its treatment can compromise bone health, leading to fracture, pain, loss of mobility, and hypercalcemia of malignancy. Bone metastasis occurs frequently in advanced prostate and breast cancers, and bony manifestations are commonplace in multiple myeloma. Osteoporosis and osteopenia may be consequences of androgen-deprivation therapy for prostate cancer, aromatase inhibition for breast cancer, or chemotherapy-induced ovarian failure. Osteoporotic bone loss and bone metastasis ultimately share a pathophysiologic pathway that stimulates bone resorption by increasing the formation and activity of osteoclasts. Important mediators of pathologic bone metabolism include substances produced by osteoblasts, such as RANKL, the receptor activator of nuclear factor kappa B ligand, which spurs osteoclast differentiation from myeloid cells. Available therapies are targeted to various steps in cascade of bone metastasis.

KW - Biochemical markers

KW - Bisphosphonates

KW - Bone health

KW - Bone metabolism

KW - Bone metastasis

KW - Bone pain

KW - Breast cancer

KW - Chemotherapy-induced bone loss

KW - Denosumab

KW - Metastatic cancer

KW - Multiple myeloma

KW - Osteoporosis

KW - Prostate cancer

KW - RANKL

UR - http://www.scopus.com/inward/record.url?scp=71949095197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71949095197&partnerID=8YFLogxK

M3 - Article

VL - 7

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - SUPPL. 7

ER -